infants with endotoxin shock the clearance of fat from the circulation may be defective and, therefore, fat should be administered with care. ABSTRACT. We evaluated carbohydrate tolerance in nine thin cystic fibrosis (CF) patients and in six controls, measuring responsiveness to the following insulinotropic secretagogues: oral glucose, IV glucose, and IV tolbutamide. Glucose responses segregated patients into two groups: Group I with normal carbohydrate tolerance associated with normal to slightly increased insulin responses, and Group I1 with impaired carbohydrate tolerance associated with insulinopenia. This latter group included one patient
with frank diabetes. The CF patients demonstrated a significant positive correlation between insulin secretion, in response to each secretagogue, and pancreatic exocrine function as measured by serum pancreatic amylase isoenzyme concentration. Pancreatic a-cell function, as reflected by basal plasma glucagon concentrations, also correlated well with exocrine function in the CF patients, excluding the diabetic individual. The enteroinsular axis of the CF group was intact as reflected by normal plasma gastric inhibitory polypeptide concentrations in Group I and by elevated levels, basally and in response to oral glucose, in the insulinopenic Group I1 patients. Furthermore, those patients with impaired tolerance demonstrated a greater magnitude of insulinopenia compared to controls following IV glucose and possibly IV tolbutamide, than following oral glucose.
Thus, these data suggest that loss of carbohydrate tolerance in patients with CF, like that seen with classical chronic pancreatitis, 1) parallels the loss of exocrine function, 2) is associated with appropriate enteroinsular sig-naling, and 3) can be detected earlier or more easily following testing with direct IV secretagogues than following oral glucose stimulation. ( CHO intolerance, as defined by an abnormal standard oral glucose tolerance test, has been reported to occur in as many as 50% of patients with CF (10, 18, 26 ). An additional 8-15% of patients may become frankly insulin-dependent (20, 24). Suggested mechanisms to account for this CHO intolerance include disordered islet cell architecture due to extension of the destructive process occurring in the exocrine structures (10) and interruption of the enteroinsular axis signal for insulin release (5) . The first implies that insulinopenia in CF results from strangulation of the islets as a result of progressive pancreatic fibrosis, as appears to be the case in some forms of pancreatitis (1 3). The second suggests that diminished insulin release is a consequence of a defect in the gastrointestinal system resulting in an abnormality of the enteroinsular axis (1). The present study was designed to clarify the role of these mechanisms and to determine the relative contributions of some of the factors which affect the functional dynamics of the endocrine pancreas. The data reveal: I) a significant positive correlation between pancreatic endocrine function (both a-and P-cell) and pancreatic exocrine function as measured by P amylase isoenzyme concentrations; 2) an intact enteroinsular axis in CF; and 3) loss of glucoreceptor-mediated insulin release prior to that of enteroinsular axis-mediated insulin release. These findings resemble the pattern of endocrine derangement seen in chronic pancreatitis.
MATERIALS AND METHODS
Patients. Nine CF patients from the University of California, Los Angeles, CF Center were studied after obtaining informed consent. In eight patients, there was no history of diabetic symptoms, glycosuria, or a first degree relative with known diabetes; one patient had a history of hyperglycemia during a recent hospitalization. The eight unselected patients had a MA of 24 Tolerance tests. Following an overnight fast, testing was begun between 0800 and 0900 h. In some patients, two intravenous tolerance tests were performed on the same morning with a 2-h rest period between tests; oral glucose tolerance was always tested alone on a separate day. The precedent for repeated intensive pancreatic P-cell stimulation was established by Vinik et al. (30) , who concluded that responsiveness to oral glucose, glucagon, and tolbutamide was preserved both in normal subjects and in patients with chronic pancreatitis. In these patients, repeated stimulations yielded almost identical peak insulin responses presumably from release of an immediately available pool of stored insulin that could be rapidly replenished.
Oral glucose tolerance test. Following 3 days of CHO intake (> 150 g/24 h), each CF patient and six controls drank Glucola (Ames Division, Miles Laboratories, Inc., Elkhart, IN), 1.75 g/ kg (maximum dose, 100 g), over a I-2-min period. Serial blood samples were obtained at 0, +30, +60, + 120, and + 180 min for glucose, insulin, and glucagon determinations in all patients. GIP levels were measured in five CF patients and five controls at the above designated times.
Intravenous glucose tolerance test. Patients received an infusion of 0.5 g/kg of dextrose (maximum dose, 25 g) over 2 min. Serial blood samples for glucose and insulin measurement were obtained at -30, -15, 0, +2, +4, +lo, +20, and +40 min. In addition, vlasma nlucagon determinations were made at 0 and 20 min during th; test-Six CF and five control subjects underwent the IVGTT.
Intravenous tolbutamide tolerance test. IV tolbutamide sodium (Orinase Diagnostic, The Upjohn Company, Kalamazoo, MI) was administered over 2 min at a dose of 15 mg/kg (maximum dose, 1 g). Serial blood samples for glucose and insulin measurement were obtained at -30, -15, 0, +2, +4, + 10, +20, and +40 min. Plasma glucagon concentrations were measured at -30, 0, +lo, +20, and +40 min. Six CF and three control subjects underwent the IVTTT.
Laboratory methods. Plasma glucose concentrations were determined by ferricyanide reduction using a Technicon Autoanalyzer. Serum insulin concentrations were measured by standard double-antibody radioimmunoassay (28) . Samples for plasma glucagon determinations were collected in benzamidine and EDTA, separated at 4" C, and kept frozen until assay. Radioimmunoassay was performed using 30K antiserum (6) . Samples for plasma GIP determinations were collected in aprotinin and EDTA, separated at 4" C, and kept frozen until assay. GIP-RIA was performed by a previously reported method utilizing rabbit antiserum at a final dilution of 1:7000 (17) .
Serum amylase isoenzymes were separated using polyacrylamide disc gel electrophoresis and quantitated by gel densitometry according to a previously published procedure (8) . The absolute concentration of P amylase isoenzyme was calculated by multplying the percentage of P amylase isoenzyme present by the total serum amylase activity as measured by a modified saccharogenic procedure (7) . All samples were obtained in the fasting state. The 95% normal range of P amylase isoenzyme in our laboratory (age, 5-47 years) is 2.8-1 1.4 starch units/liter. CF patients with significant pancreatic insufiiciency confirmed by duodenal intubation have values below the normal range after 1.5 years of age, while CF patients with adequate pancreatic function have values in or above the normal range. We have established that serum P amylase isoenzyme concentrations in CF patients correlate well with 72-h fecal fat absorption and duodenal bicarbonate output, the standard tests for assessment of pancreatic exocrine function (9) .
Statistical significance was determined by Student's t test for paired or unpaired observations where appropriate. Correlation coefficients were determined by standard linear regression analysis. The above calculations, as well as compilation of integrated areas under insulin response curves, were performed using the HP-97 programmable printing calculator (Hewlett Packard, Corvallis, OR). All data are expressed as mean +. SEM.
RESULTS
Following oral glucose ingestion, CF patients ( n = 8) separated into two groups based on glucose responses: Group I was normal carbohydrate tolerance (n = 3) and Group I1 was impaired CHO tolerance (n = 5) (Fig. IA) . The diabetic CF patient is depicted separately in this and subsequent figures. Although mean plasma glucose concentrations in Group I were greater than in controls at 60 and 120 min ( p < 0.001), these values were not within ranges considered to represent abnormal glucose tolerance for late adolescence (1 9). In Group I1 patients, mean plasma glucose concentrations were significantly greater than in controls at 30 ( p < 0.05), 60, and 120 min (both p < 0.001). These Group I1 patients had 1 -h plasma glucose concentrations ranging between 188 and 284 mg/dl and 2-h levels between 176 and 258 mg/dl.
The integrated glucose response in Group I1 (32.3 + 2.18 g/dl. min) was greater than that in Group I (24.2 + 0.96 g/dl. min; p < 0.05) as were the mean plasma glucose responses at 60 and 120 min (both p < 0.05). The diabetic CF patient had markedly abnormal glucose responses (Fig. IA) . When areas under the insulin response curve were compared, the mean area in Group I (1 2.1 2 2.56 milliunits/ml . min) was significantly greater than the mean of controls (6.60 + 0.82 milliunits/ml. min) ( p < 0.05).
Contrastingly, the mean area under the insulin response curve in Group I1 subjects (4.20 + 0.52 milliunits/ml.min) was significantly less than that of controls ( p < 0.02). This was a consequence of both decreased peak levels early in the test ( p < 0.02 at 30 min and p < 0.0 l at 60 min) and delay in peak insulin responses until 120 min (Fig. 1 B) . The least incremental insulin response was seen in the diabetic CF subject (2.15 milliunits/ ml . min).
Following intravenous glucose, mean plasma glucose concentrations in both CF groups were not significantly different from those of controls ( Fig. 2A) . While Group I patients (n = 3) had a mean area under the insulin response curve (2.23 + 0.81 milliunits/ml.min) which was similar to that seen in controls (1.43 + 0.25 milliunits/ml . min) ( p > 0.05), Group I1 patients (n = 3) had significantly less insulin output (0.36 + 0.027 milliunit/ml.min) than did controls ( p < 0.02) (Fig. 2B ). An unusual finding in two Group I patients was that their serum insulin concentrations remained elevated after 40 min. The diabetic CF patient did not undergo this test.
In response to intravenous tolbutamide, the following mean plasma glucose decrements were observed: controls (n = 3) 44.3 + 3.30 mg/dl; Group I (n = 3), 17.3 + 5.80 mg/dl; and Group I1 (n = 3), 4.70 + 2.90 mg/dl. Both the mean Group I decrement and the mean Group I1 decrement were significantly less than those of controls ( p < 0.02 and 0.001, respectively) while there was no difference between Group I and Group I1 ( p > 0.05) (Fig.   3A) . The diabetic CF patient had a maximal decrement of 15 mg/dl which was delayed in onset compared to the controls.
Insulin responses of patients in Group I (1.34 + 0.25 milliunits/ ml. min) were similar to those of controls (1.43 + 0.67 milliunits/ ml.min) ( p > 0.05). Although mean area under the insulin response curve was lower in Group I1 patients (0.54 + 0.056 milliunit/ml . min), this was not statistically different from either controls or Group I ( p > 0.05) (Fig. 3B) . Again, the least incremental insulin response was seen in the one diabetic subject (0.39 milliunit/ml. min).
Pancreatic exocrine function was assessed by determination of P amylase isoenzyme levels and then correlated to insulin and glucagon activity. The relationship between P amylase isoenzyme concentration and insulin secretion in response to the three insulinotropic secretagogues is shown in Figure 4 , A-C. In the CF patients, a significant correlation is demonstrated for each agent: oral glucose (n = 9) (R = 0.92, p < 0.00 I); IV glucose (n = 5) (R = 1.00, p < 0.001); and IV tolbutamide (n = 6) (R = 0.93, p < 0.01). No correlation between insulin secretion and P amylase isoenzyme levels was evident in the control population ( p > 0.05), although control values tended to fall between those of the two CF groups.
Evaluation of pancreatic a-cell function demonstrated that the basal plasma glucagon concentrations in the eight nondiabetic CF patients also showed significant positive correlation with their P amylase isoenzyme concentrations (R = 0.87, p < 0.01) ( correlation of P amylase isoenzyme and basal glucagon ( p > 0.05). The one diabetic CF subject had a mean basal plasma glucagon concentration of 337 + 62 pg/ml ( n = 3).
To quantitate enteroinsular axis function, GIP: insulin ratios following OGTT were correlated (Table I ). The G1P:insulin ratios in the two Group I1 carbohydrate-intolerant patients were greater than 3SD above the mean control value, whereas there was no significant difference between the two Group I patients and controls. Additionally, a relatively greater impairment (mean of 75%) ( p < 0.02) of insulin secretion was seen in Group I1 patients versus controls following IV glucose than following both oral glucose (mean of 36%) (p < 0.02) and IV tolbutamide (mean of 62%) ( p > 0.05) (Fig. 6) .
DISCUSSION
In the nine CF patients studied herein, we have demonstrated two general patterns of CHO tolerance in response to insulinotropic secretagogues: normal CHO tolerance with appropriate to exaggerated insulin responses (Group I) and decreased CHO tolerance associated with insulinopenia (Group 11), with one patient manifesting a frankly diabetic pattern. That these heterogeneous insulin responses may be due to variation in residual pancreatic integrity is suggested by the significant positive correlations observed between P amylase isoenzyme concentrations and insulin secretion. This parallel dysfunction of pancreatic exocrine function and P-cell activity in CF patients is supported by the recent studies of Antonelli et al. (2) , who used serum immunoreactive trypsin and fasting C-peptide concentrations to assess pancreatic exocrine and endocrine functions, respectively.
Basal a-cell function in our patients, as assessed by mean fasting plasma glucagon concentrations, correlated significantly with P amylase isoenzyme concentrations in these patients, excluding the diabetic individual. We and others have previously noted that hyperglucagonemia is not a feature of mild carbohydrate intolerance in C F (16) , but may be present in markedly insulinopenic C F patients (23, 29) and in patients with pancreatitis (1 1). We interpret these data to suggest that ambient plasma glucagon concentrations are suppressed by the interaction between glucose and insulin over a range of pancreatic insufficiency. However, when insulin loss is profound, hyperglucagonemia supervenes, suggesting preservation of some residual acell activity. Since one Group I CF patient also showed a dissociation between the P amylase isoenzyme concentration and insulin responsiveness, demonstrating low exocrine reserve with normal insulin levels, the data suggest that exocrine dysfunction precedes P-cell loss and that P-cell precedes a-cell loss.
Of note is that the plasma glucose responses during the IVGTT and the IVTTT were similar in Groups I and I1 despite markedly different insulin responses. Thus, the hypoinsulinemic patients disposed of IV glucose as effectively as the normoinsulinemic group. While thin hypoinsulinemic CF patients may have enhanced insulin sensitivity by virtue of increased receptor number (15) , glucose disposal might be expected to be similar after oral and IV glucose. In fact, if differences occur, recent evidence in normal man suggests that glucose ingested orally is disposed of more efficiently than glucose administered intravenously (22) . Ten to 15% of oral glucose can be taken up by the liver on first passage (27) . If liver dysfunction develops, which is a common occurrence in C F (2 l), peripheral disposal of an intravenous load of glucose may be normal whereas disposal of an orally ingested load could be delayed. Thus, Group I patients, with greater insulin output than that of controls following oral glucose ingestion, may be responding to diminished hepatic insulin sensitivity secondary to associated liver damage.
Although GIP concentrations in CF have been reported as exaggerated in response to oral glucose (25) and diminished following a milk stimulus (I), our data suggest that there is an appropriately functioning enteroinsular axis with normal GIP responses in the CHO-tolerant Group I patients and enhanced basal and oral glucose-stimulated levels in CHO-intolerant Group 11, similar to that seen in chronic pancreatitis (4) . These results confirm the negative feedback relationship proposed for GIP and insulin (3). Both previously cited CF studies reported only insulinopenic patients and the latter study relied on intestinal hydrolysis of milk fat for stimulation of GIP secretion. Although all patient groups showed decreased insulin secretion in response to IV glucose compared to oral glucose or IV tolbutamide, Group I1 C F patients produced significantly less insulin after IV glucose than after oral glucose compared to respective control responses. This suggests earlier or greater loss of glucoreceptor activity compared to "enteroreceptor" (GIP) activity. Although we did not find statistically different responses to IV tolbutamide between patient groups or compared to controls, which may reflect small sample size, loss of insulin responsiveness to tolbutamide in Group I1 was intermediate between that seen with oral and IV glucose.
Thus, our studies suggest that the pancreatic endocrine disturbances in CF may be similar to those described in chronic pancreatitis, supporting the disruption hypothesis. The degree of insulinopenia appears to mirror the degree of exocrine insufficiency. Similarly, insulinopenia, associated with diminished content of amylase, chymotrypsin, and lipase in pancreatic juice following cholecystokinin-pancreozymin stimulation in seven patients with chronic pancreatitis, has been reported by Kalk et al. (14) . Additionally, loss of P-cell receptor recognition of intravenous glucose, and possibly tolbutamide, may antedate loss of sensitivity to enteroinsular (GIP) mediated insulinotropic secretagogues in our CF subjects and in patients with chronic pancreatitis (1 2).
